CTIS2023-509717-36-00Active, not recruitingPhase 1
Monotherapy with a P2Y12 inhibitor followed by a direct-acting oral anticoagulant in patients with ATRial fIbrillation undergoing suprafleX Cruz coronary stent implantation (MATRIX-2) - MATRIX-2
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Sponsor
- Insel Gruppe AG
- Enrollment
- 1,690
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 to 65+ (—)
- Sex
- All
Inclusion Criteria
- •Age = 18 years, Atrial fibrillation or flutter with an indication for oral anticoagulation using direct-acting oral anticoagulants (DOACs) for = 12 months, Successful percutaneous coronary intervention in at least 1 lesion within the previous 7 days with no remaining lesions intended for treatment, Free from major adverse events post qualifying PCI, including new onset chest pain suspected to be of ischemic origin, acute or subacute stent thrombosis, new-onset neurological signs or symptoms, Written informed consent
Exclusion Criteria
- •Planned staged percutaneous intervention procedure, Moderate and severe hepatic imparment (Child-Pugh Class B or C) or any hepatic disease associated with coagulopathy, Any hypersensitivity or contraindications for direct oral anticoagulant or dual antiplatelet therapy with aspirin and a P2Y12 inhibitor, Any of the following abnormal local laboratory results prior to randomization: platelet count < 50x10^9/L or hemoglobin <8 g/dL, Known pregnancy or breast-feeding patients, Life expectancy <1 year due to other severe non-cardiac disease, Planned surgery including coronary artery bypass grafting within the next 6 months, Cardioversion for treatment of atrial fibrillation within 1 month prior to inclusion or planned cardioversion, Atrial fibrillation ablation procedure within 2 month prior to inclusion or planed atrial fibrillation ablation procedure, Prior mechanical valvular prosthesis implantation, Deep vein thrombosis/pulmonary embolism, at least moderately severe mitral stenosis or other clinical conditions than atrial fibrillation requiring long-term oral anticoagulation, Stroke within 1 month prior to randomization, Hemodynamic instability (persistent systolic blood pressure below 90 mmHg, continuous infusions of catecholamines, clinical signs of hypoperfusion and/or use of percutaneous left ventricular assist devices), Uncontrolled severe hypertension with a systolic blood pressure (BP) = 180 mmHg and/or diastolic BP = 120 mmHg, Severe renal impairment with estimated creatinine clearance (CrCL) < 15 mL/min or on dialysis
Investigators
Similar Trials
Withdrawn
Phase 4
P2y12-receptOr antagonist therapy in patients with coronary artery disease undergoing Percutaneous coronary intervention using an genotype-guided treatment STRATEGYchronic coronary syndromeNL-OMON52565Sint Antonius Ziekenhuis3,526
Recruiting
Phase 4
Tailoring P2Y12 Inhibiting Therapy in Patients requiring Oral Anticoagulation after undergoing Percutaneous Coronary Intervention: The Switching Anti-Platelet and Anti-Coagulant Therapy - 2 Studycoronary artery diseasepercutaneous coronary intervention1001108210003216NL-OMON52027niversity of Florida College of Medicine50
Active, not recruiting
Phase 1
Tailoring blood thinners after percutaneous coronary interventioEfficacy of antiplatelet therapy after percutaneous coronary intervention in patients using oral anticoagulantsEUCTR2021-001418-12-NLniversity of Florida84
Active, not recruiting
Phase 1
REperfusion with P2Y12 inhibitors in addition to mEchanical thRombectomy for perFUsion imaging selected acute Stroke patiEnts : a multicentric randomized controlled trialpatients with a clinical diagnosis of AIS consecutive to LVO between 0 and 24 hours of symptom onset and selected by perfusion imagingEUCTR2020-005451-20-FRFondation A. de Rothschild Hospital368
Active, not recruiting
Phase 1
Reperfusion with P2Y12 inhibitors in addition to mechanical thrombectomy for perfusion imaging selected acute stroke patients : a multicentric randomized controlled trialCTIS2024-516163-88-00Fondation A De Rothschild368